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OBJECTIVE: Scarce data are available on the occurrence of symptomatic intracranial hemorrhage related to
intravenous thrombolysis for acute stroke in South America. We aimed to address the frequency and clinical
predictors of symptomatic intracranial hemorrhage after stroke thrombolysis at our tertiary emergency unit in
Brazil.
METHOD: We reviewed the clinical and radiological data of 117 consecutive acute ischemic stroke patients
treated with intravenous thrombolysis in our hospital between May 2001 and April 2010. We compared
our results with those of the Safe Implementation of Thrombolysis in Stroke registry. Univariate and mul-
tiple regression analyses were performed to identify factors associated with symptomatic intracranial
transformation.
RESULTS: In total, 113 cases from the initial sample were analyzed. The median National Institutes of Health Stroke
Scale score was 16 (interquartile range: 10-20). The median onset-to-treatment time was 188 minutes (interquartile
range: 155-227). There were seven symptomatic intracranial hemorrhages (6.2%; Safe Implementation of
Thrombolysis in Stroke registry: 4.9%; p=0.505). In the univariate analysis, current statin treatment and elevated
National Institute of Health Stroke Scale scores were related to symptomatic intracranial hemorrhage. After the
multivariate analysis, current statin treatment was the only factor independently associated with symptomatic
intracranial hemorrhage.
CONCLUSIONS: In this series of Brazilian patients with severe strokes treated with intravenous thrombolysis in a
public university hospital at a late treatment window, we found no increase in the rate of symptomatic intracranial
hemorrhage. Additional studies are necessary to clarify the possible association between statins and the risk of
symptomatic intracranial hemorrhage after stroke thrombolysis.
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INTRODUCTION
Acute ischemic stroke is one of the leading causes of
mortality and disability worldwide and represents a life-
changing and ominous event for many patients (1). Currently,
intravenous thrombolysis with tissue plasminogen activator
(TPA) is the only approved medical therapy for acute
ischemic stroke aimed at arterial recanalization. However,
the use of such therapy has been relatively low, partially due
to its narrow therapeutic window but also because of
concerns about the risk of symptomatic intracranial hemor-
rhagic transformation (SIH), which may be associated with
clinical deterioration and death (2-4).
Reliable predictors of SIH are still under debate. In a
systematic review that included 12 studies, there was
considerable variance between results, and no predictor of
SIH was common to all studies (5). Defining the accurate
risk factors for SIH could increase the safety of TPA
treatment for stroke and should eventually reduce the
unnecessary concerns about its risks.
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Stroke is the main cause of death in Brazil, which has a
higher age-adjusted mortality rate related to this condition
than other South American countries (6-8). Little information
exists on the safety of thrombolysis and the occurrence of
SIH in South America (9-11). Recent studies found alarming
results on public stroke awareness, delays in hospital
admission and high stroke-related in-hospital mortality in
Brazil (12,13). Nevertheless, there are few data about the
safety of IV TPA for stroke in the country. SIH may be more
common among more severe stroke patients (14), and the
impact of late admission and, consequently, of late onset-to-
needle time on the safety of IV TPA is also amatter of concern.
In this study, we aimed to determine the frequency of SIH
and the factors associated with its occurrence among
patients with an acute ischemic stroke treated with IV
TPA at our public tertiary emergency unit in Brazil.
PATIENTS AND METHODS
We reviewed our institutional prospective stroke registry
to identify all patients treated with IV TPA at the emergency
unit of our hospital from May 2001 to April 2010. This
prospective registry and this study were approved by the
local institutional review board. Demographic data, cere-
brovascular risk factors, prior medical history and medical
therapy, clinical data, and relevant laboratory data were
collected from this prospective registry by the investigators.
Stroke severity was measured using the National Institutes
of Health Stroke Scale (NIHSS) and assessed by certified
medical staff from the institution (15). The exclusion criteria
were predefined as the lack of data for onset-to-treatment
time, admission NIHSS score or neuroimaging scans.
Intravenous thrombolysis was administered in accordance
with an institutional protocol, which was based on the
National Institute of Neurological Disorders and Stroke
(NINDS) trial and the European Cooperative Acute Stroke
Study-3 (ECASS-3) trial (16,17). Informed consent was
obtained from all patients or their proxy. NIHSS was assessed
every 15 minutes during infusion, every hour during the first
6 hours, and every 6 hours during the first 48 hours after
treatment. The monitoring and control of blood pressure were
performed according to the Brazilian Consensus for the
Thrombolysis in Acute Ischemic Stroke, which uses the same
monitoring strategy and blood pressure thresholds for
intervention as the NINDS trial protocol and the American
Stroke Association guidelines for the early management of
adults with acute stroke (18,16,19). The Brazilian protocol
includes sodium nitroprusside and metoprolol as optional
drugs for blood pressure control because labetalol, intrave-
nous nicardipine, and nitropaste are not widely available in
Brazil. In our hospital, sodium nitroprusside and metoprolol
were used for blood pressure control. A control brain
computed tomography scan was obtained 24 to 48 hours after
treatment or immediately for neurological deterioration. All
protocol violations were reviewed and registered by the main
investigators. The results from our institution were compared
with those of the Safe Implementation of Thrombolysis in
Stroke – International Stroke Thrombolysis Registry (SITS-
ISTR), which was published after the ECASS-3 trial and in-
cluded patients within the 4.5-hour window of treatment (20).
Image review
All of the images were independently reviewed by the
main investigators (PTC, BLS, and FAD). When present,
intracranial hemorrhages were categorized according to the
ECASS classification system (hemorrhagic infarction (HI)
type 1, HI type 2, parenchymal hematoma (PH) type 1, and
PH type 2) (21). In the event of disagreement between
investigators, images were further reviewed by an experi-
enced stroke neurologist (OMP) for consensus. SIH was
defined as any intracranial hemorrhage associated with an
increase of 4 points or more on the NIHSS score or death,
according to the criteria applied in the ECASS-2 trial (22).
Statistical analysis
In the univariate analysis, Fisher’s exact test was used for
categorical data, and Wilcoxon’s rank-sum test was used for
quantitative data. A forward stepwise logistic regression
analysis was used to identify the independent predictors
of SIH among the variables with a p-value,0.1 in the
univariate analysis. The Spearman correlation coefficient
(rs) was used to evaluate the correlations between quanti-
tative variables. All of the statistical analyses were
performed with the SPSS package (version 15.0 for
Windows; Chicago, Illinois, USA).
RESULTS
Between May 2001 and April 2010, 117 consecutive
patients with acute ischemic stroke were treated with IV
TPA in the emergency department of our institution. Four
patients were excluded from the current analysis because
relevant data regarding treatment were unavailable. None
of those patients had SIH. The mean age in the remaining
sample was 63¡12.8 years old. The median onset-to-
treatment time was 188 minutes [interquartile range
(IR) = 155-227]. This median onset-to-treatment time was
higher than the SITS-ISTR ,3 h cohort [140 (IR = 114-165);
p,0.001] and lower than the 3-4.5 h cohort [205 (IR= 190-
229); p= 0.048]. Five (4.4%) patients received IV TPA within
90 minutes, 47 (41.6%) from 91-180 minutes, 51 (45.1%) from
181-270 minutes, and 10 (8.8%) after 270 minutes. The
median admission NIHSS score was 16 (IR = 10-20). Our
sample had more severe strokes than the SITS-ISTR in both
treatment cohorts [,3 h cohort: 12 (IR= 7-17), p,0.001; 3-
4.5 h cohort: 10 (IR= 6-15), p,0.001]. Twenty-eight (24.8%)
patients had an NIHSS score equal to or less than 10, 60
(53.1%) from 11-20, 19 (16.8%) from 21-30, and six (5.3%)
scored greater than 30. The demographic characteristics and
clinical and laboratory data at the time of admission are
shown in Table 1. Our sample had more prior stroke events
and concurrent comorbidities and higher admission blood
pressure than the SITS-ISTR. SIH occurred in 7 patients
(6.2%), which were categorized as 2 PH-1 and 5 PH-2. SIH
was related to in-hospital death (p= 0.005). Using the same
ECASS-2 definition for SIH, we did not observe more
hemorrhages compared with the SITS-ISTR (6.2% vs. 4.9%;
p = 0.505).
Some patients received IV TPA despite having protocol
violations: nine patients (8.0%) were older than 80 years old;
ten (8.8%) patients received IV TPA after 270 minutes; and
six (5.3%) patients had glycemia levels equal to or greater
than 400 mg/dL. None of the patients above 80 years old
suffered an SIH. One of the six patients with glycemia levels
above 400 mg/dL suffered an SIH (16.6%; SIH in patients
with glycemia #400 mg/dL: 5.4%; p = 0.325). Five patients
with NIHSS scores between 11-20, two patients with scores
between 21 and 30, and none of the patients with scores
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greater than 30 or less than 11 experienced an SIH. Three
patients with an onset-to-needle time between 91 and 180
minutes and four patients with an onset-to-needle time
between 181 and 270 minutes had an SIH. SIH did not occur
among patients treated within 90 minutes or after 270
minutes.
Ten patients were taking statins at the time of admission,
and three of the ten patients suffered an SIH. Patients
currently using statins were more likely to have hyperlipi-
demia (p,0.001) and congestive heart failure (p = 0.042). In
the univariate analysis, prior statin use was associated with
SIH, and there was a trend toward an association between
greater stroke severity and SIH (Table 2). After the multi-
variate analysis, the prior use of statins was the only factor
independently associated with SIH (OR=3.8; 95% confi-
dence interval: 2.5-8.2; p,0.001).
DISCUSSION
In this series of acute ischemic stroke patients treated with
IV TPA in a single public university hospital of Brazil, we
observed no increase in the SIH occurrence compared with
the more recent data from the SITS-ISTR. Our patients had
severe neurological deficits and a late onset-to-needle time.
Patients with SIH had greater NIHSS scores at the time of
admission, although this difference did not reach statistical
significance. We found no association between SIH and age
greater than 80 years old or onset-to-treatment time. Prior
use of statins was the only factor independently associated
with SIH.
A large pooled analysis of the main trials of IV TPA in
acute ischemic stroke did not show a correlation between
onset-to-needle time and SIH occurrence (23). In the NINDS
trial, elevated NIHSS scores predicted SIH (14), but the
ECASS-2 results did not confirm this association (4).
Although IV TPA seems to remain equally safe for ischemic
stroke treatment throughout the 4.5-hour treatment win-
dow, its functional benefit decreases with prolonged onset-
to-needle time (23-25). More than half of our sample was
treated after 3 hours of symptom onset, and few patients
received IV TPA in the first ‘golden hour’. In the last decade,
a hierarchical network between emergency units has been
implemented in the Brazilian emergency care systems.
However, this referral network was not specifically
designed for acute stroke care, and there were no unified
multi-institutional protocols. We believe that this lack may
have contributed to delays in acute stroke recognition and
referral to our hospital in the first years of implementation
of this emergency network. More recently, there has been an
important endeavor (with major input from stroke neurol-
ogists) to improve pre-hospital care and organize regional
stroke networks in Brazil (26).
Although we may conclude that acute stroke thrombo-
lysis can be safely performed, even in severe patients treated
within a rather late treatment window, the true efficacy of
IV TPA in this setting is most likely less beneficial. There are
striking demographic disparities among Brazilian regions,
and nationwide clinical registries are necessary to address
this issue (27). Fortunately, the Safe Implementation of
Thrombolysis in Stroke – Iberoamerican Cerebrovascular
Diseases Society (SITS-SIECV) Stroke Registry has been
recently created and will show broader results about the
safety and efficacy of IV TPA use for stroke treatment in
Latin America.
We observed a high frequency of baseline comorbidities
in our sample. Indeed, our patients were more likely to have
arterial hypertension, diabetes, dyslipidemia, heart disease
Table 1 - A comparative analysis of patient demographic,
medical history, and clinical and laboratory data.
Present study SITS-ISTR p-value
Female sex 47.8% 39.7% 0.083
Hypertension 80.5% 59.2% 0.007
Diabetes mellitus 31.9% 16.0% ,0.001
Hyperlipidemia 21.2% 35.1% 0.002
Obesity 23.9% NA -
Smoking 28.3% 25.6% 0.517
Alcohol abuse 17.7% NA -
Atrial fibrillation 16.8% 22.9% 0.144
Congestive heart
failure
15.0% 7.6% 0.007
Ischemic heart disease 16.8% NA -
Prior stroke 18.6% 10.3% 0.003
Chagas’ disease 5.3% NA -
Current aspirin use 29.2% 29.4% 0.999
Current warfarin use 6.2% NA -
Current statin use 8.8% NA -
SBP (mmHg) 156 (140-180) ,3 h=150 (136-165)
3-4.5 h=150 (136-166)
p= 0.007
DBP (mmHg) 90 (80-104) ,3 h=81 (74-90)
3-4.5 h=80 (74-90)
p,0.001
p,0.001
NIHSS 16 (10-20) ,3 h=12 (7-17)
3-4.5 h=10 (6-15)
p,0.001
p,0.001
Glycemia (mg/dL) 114 (101-162) ,3 h=117 (102-140)
3-4.5 h=117 (103-142)
p= 0.011
p= 0.011
SITS-ISTR: Safe Implementation of Thrombolysis in Stroke-International
Stroke Thrombolysis Registry. NA: not available. SBP: systolic blood
pressure at the time of admission. DBP: diastolic blood pressure at the
time of admission. NIHSS: National Institutes of Health Stroke Scale.
Categorical variables are shown as relative frequencies (%). Numerical
variables are shown as medians (interquartile range).
Table 2 - Univariate analysis.
No SIH (n= 106) SIH (n = 7) p-value
Male sex 55 (51.9%) 4 (57.1%) 0.999
Age 63.0¡13.1 62.9¡7.6 0.979
NIHSS* 15 (10-20) 19 (16-22) 0.083
Onset-to-treatment* 185 (155-227) 190 (100-227) 0.560
Hypertension 85 (80.2%) 6 (85.7%) 0.999
Diabetes 35 (33.0%) 1 (14.3%) 0.428
High cholesterol 21 (19.8%) 3 (42.9%) 0.164
Smoking 31 (29.2%) 1 (14.3%) 0.671
Alcohol abuse 20 (18.9%) Zero 0.350
Prior stroke 20 (18.9%) 1 (14.9%) 0.999
Atrial fibrillation 18 (17.0%) 1 (14.9%) 0.999
Chagas’ disease 6 (5.7%) Zero 0.999
Congestive heart failure 16 (15.1%) 1 (14.9%) 0.999
Ischemic heart disease 19 (17.9%) Zero 0.599
Obesity 26 (24.5%) 1 (14.9%) 0.999
Aspirin use 32 (30.2%) 1 (14.9%) 0.671
Warfarin use 7 (6.6%) Zero 0.999
Statin use 7 (6.6%) 3 (42.9%) 0.015
SBP (mmHg) 160.5¡34.2 157.1¡27.3 0.800
DBP (mmHg) 91.2¡22.8 97.0¡18.0 0.543
Glycemia (mg/dL) 142.9¡64.3 101.3¡35.3 0.121
SIH: symptomatic intracranial hemorrhage. NIHSS: National Institutes of
Health Stroke Scale. SBP: systolic blood pressure at the time of admission.
DBP: diastolic blood pressure at the time of admission. Categorical
variables are expressed as events (percentage). Numerical variables are
expressed as the mean¡standard deviation. *Expressed as median
(interquartile range).
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and higher blood pressure at the time of admission compared
with the patients in the SITS-ISTR. Nevertheless, this profile
was not related to a more frequent SIH occurrence in this
study. Prior diabetes and congestive heart failure have been
associated with SIH in some studies, but this association has
not been consistently confirmed by others (5). The presence of
severe comorbidities may be a surrogate marker for more
critical underlying strokes and also suggests an important
opportunity to reduce stroke recurrence.
The effect of prior statin use on SIH occurrence in acute
ischemic stroke patients treated with recanalization therapies
is controversial. The prolonged use of statins and low
cholesterol levels have been associated with an increased
risk of spontaneous hemorrhagic stroke, although a clear
explanation for such an association has not been fully
established (28). This relationship may be due to non-lipid-
related effects. In clinical and experimental studies, statins
have been observed to have anti-thrombotic and pro-
fibrinolytic effects (29,30). HMG-CoA reductase inhibitors
decrease platelet aggregation and reduce fibrinogen and
prothrombin levels and their conversion to active forms
(31,32). A positive relationship between prior statin use and
SIH in intra-arterial thrombolysis-treated patients has been
reported (33). However, there was no relationship between
prior statin use and SIH or good functional outcome in a large
prospective cohort of acute ischemic stroke patients treated
with IV TPA (34). One study including patients treated with
IV TPA, intra-arterial thrombolysis and endovascular embo-
lectomy found that lower admission low-density lipoprotein
levels but not prior statin use were related to SIH (35).
Recently, a large pooled analysis found that statin users had
more ECASS2-defined SIH, although this positive association
was no longer significant after a multivariate analysis and
adjustment for imbalances between the groups of statin users
and non-statin users (36). These conflicting results could be
related to ethnic disparities between the populations of these
studies. In fact, it has been shown that ethnicity may have
striking effects on statin pharmacokinetics (37). We believe
that further studies would be necessary to answer this
controversy.
The main limitations of our study include its small sample
size and its single-center and retrospective design. The fact
that variables such as age and stroke severity were not
significantly related to SIH may be due to low study power
because there were only seven hemorrhages. Larger studies
are required before conclusions on the relationships between
clinical variables and SIH can be drawn. Additionally, the
blood pressure values during the first 48 hours after treat-
ment were not assessed, and an imbalance of adequate blood
pressure control between the subgroups is possible. We were
also not able to retrieve cholesterol levels before or during the
acute phase of stroke in many patients, and this precluded
the analysis of the relationship between cholesterol levels and
SIH. Furthermore, it is probable that our results may not
reflect the acute stroke treatment conditions in other regions
of Brazil.
Intravenous thrombolysis remains one of the few medical
therapies for acute ischemic stroke. Nevertheless, few
patients admitted to emergency departments receive
thrombolytic treatment in developing countries. Scarce lay
knowledge about stroke symptoms, ineffective health
coverage and non-organized stroke care are contributing
to this scenario (2,7,12). In fact, only recently has alteplase
been reimbursed in the public health system in Brazil.
Nevertheless, important efforts for the promotion of public
stroke awareness and the organization of national and
regional stroke networks in Brazil have already shown
positive and promising results, with a reduction in stroke
rate and mortality (38).
In this study, we found that, despite the increased
severity of strokes and delayed admissions, acute stroke
treatment with IV TPA can be safely performed in Brazil
without an increased risk of SIH. In severe, late-treated
patients with acute stroke, statin use may be associated with
the occurrence of SIH. However, further studies are
necessary to clarify this association.
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